Morgan Petronelli is an associate editor for 

and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

She enjoys working out, listening to music, and playing with her dog Scout. You can reach her at 

Podcasts

This episode of The Cutaneous Connection podcast, sponsored by Incyte, explores the world of vitiligo. From symptoms to current treatment dissatisfaction and the latest research, Pearl Grimes, MD, FAAD, explains where we are now with this pigmentary disorder and where we are headed.

The Cutaneous Connection: Deep Dive Into the World of Vitiligo

Armand Butera is the assistant editor for 

. He attended Fairleigh Dickinson University and graduated with a degree in communications with a concentration in journalism. Prior to graduating, Armand worked as the editor-in-chief of his college newspaper and a radio host for WFDU. He went on to work as a copywriter, freelancer, and human resources assistant before joining 

. In his spare time, he enjoys reading, writing, traveling with his companion and spinning vinyl records. Email him at 

Articles

Investigators write that methods such as dermatoscopy can result in early recognition of unstable patches and lead to appropriate medical treatment for patients with vitiligo.

Serial Assessment of Vitiligo Patches Results in Early Recognition

A new study showed about half of all vitiligo patients from a care system were burdened with the sleeping disorder.

Vitiligo Linked to Insomnia Risk

John Jesitus is a medical writer based in Westminster, CO.

Innovations include underserved populations, acne, and advanced applications. 

New Frontiers in Laser, Light, Optical Devices 

and joined the MJH Life Sciences team in April 2021. She graduated from Kent State University in 2018 with a bachelor's degree in journalism and a minor in sociology. Linda used to work as a creative writer for 

 and was a technical writer/regulatory specialist/purchasing agent at GM Industrial before coming on to the team. She enjoys reading, traveling, and learning new perspectives. You can reach her at 

 In this first part of our coverage of “The Skin of Color Update Pre-Conference Virtual Symposium” held August 3, we review challenging cases of melasma, vitiligo, and post-inflammatory hyperpigmentation in skin of color patients.   
 

Challenging Cases in Skin of Color Patients

Camp Wonder, a camp that supports kids with skin disease and is sponsored by Galderma, is celebrating their 20th year of operations this week. 

Camp Wonder Celebrates 20 Years

Arcutis Biotherapeutics announced early termination of its phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo citing to inadequate local drug delivery to the skin.

Arcutis Biotherapeutics to Terminate Phase 2a Vitiligo Study

Jonathan Alicea is an assistant editor for 

. He graduated from Princeton University with a degree with English and minors in Linguistics and Theater. He spends his free time writing plays, playing PlayStation, enjoying the company of his 2 pugs, and navigating a right-handed world as a lefty. You can email him at 

The COVID-19 pandemic had forced vitiligo patients to delay treatments; however, not much is known about the effects of delaying on disease course.

Potential Risk of Progression, Recurrence With Delayed Vitiligo Treatment 

Ruxolitinib cream (Jakafi, Incyte) demonstrated positive results in 2 phase 3 studies investigating the topical for treatment of vitiligo in patients 12 years and older

Ruxolitinib Safe, Effective for Vitiligo in Adolescents, Adults

Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo. 

Pigmentary Disorders